. Author manuscript; available in PMC: 2010 May 1.

Published in final edited form as: Eur J Immunol. 2009 May;39(5):1280–1287. doi: 10.1002/eji.200839002

Table 1. Clinical and experimental characteristics of the study participants^a).

Procedure^b)	Donor	HIV RNA, copies/ml	CD4⁺:CD8⁺ ratio	CD4⁺ cells/μl	CD8⁺ cells/μl
IL-10	A	21000	0.20	300	1530
	B	5600	0.23	380	1670
	C	9500	0.23	540	2400
	D	5500	0.32	270	840
	E	200	0.14	190	1380
	F	1100	0.41	340	830
	G	7600	0.35	1040	2960
	H	500	0.98	580	590
	I	3300	0.47	770	1630
	J	97000	0.23	300	1310
	K	17000	0.57	1210	2140
	L	190000	0.45	620	1370

	Median	6600	0.34	460	1455
	Range	200 - 190000	0.14 - 0.98	190 - 1210	590 - 2960

IFN-γ	M	600	0.66	270	410
	N	170000	0.28	280	1010
	O	2600	1.58	840	530
	P	19000	0.36	400	1110
	Q	110000	0.16	180	1100
	R	87000	0.65	350	540
	S	12000	0.83	571	686
	T	250000	0.19	428	2222
	U	160000	0.14	198	1370
	V	9500	0.33	363	1091
	W	91000	0.26	335	1282

	Median	87000	0.33	350	1091
	Range	600 - 250000	0.14 - 1.58	180 - 840	410 - 2222

^a)

Presented are the donors included in co-culture experiments.

^b)

Refers to whether the PBMC from the respective donor were subjected to IL-10- or IFN-γ enrichment.

Table 1. Clinical and experimental characteristics of the study participantsa).